Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Champions Oncology, Inc. before investing.

In this article, we go over a few key elements for understanding Champions Oncology, Inc.’s stock price such as:

• Champions Oncology, Inc.’s current stock price and volume
• Why Champions Oncology, Inc.’s stock price changed recently
• Upgrades and downgrades for CSBR from analysts
• CSBR’s stock price momentum as measured by its relative strength

About Champions Oncology, Inc. (CSBR)

Before we jump into Champions Oncology, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Want to learn more about Champions Oncology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Champions Oncology, Inc..

Champions Oncology, Inc.’s Stock Price as of Market Close

As of April 25, 2025, 12:27 PM, CST, Champions Oncology, Inc.’s stock price was $7.945.

Champions Oncology, Inc. is up 4.4% from its previous closing price of $7.610.

During the last market session, Champions Oncology, Inc.’s stock traded between $7.880 and $8.200. Currently, there are approximately 13.70 million shares outstanding for Champions Oncology, Inc..

Champions Oncology, Inc.’s price-earnings (P/E) ratio is currently at 16.7, which is low compared to the Life Sciences Tools & Services industry median of 33. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Champions Oncology, Inc. Stock Price History

Champions Oncology, Inc.’s (CSBR) price is currently down 8.47% so far this month.

During the month of April, Champions Oncology, Inc.’s stock price has reached a high of $9.170 and a low of $7.010.

Over the last year, Champions Oncology, Inc. has hit prices as high as $11.990 and as low as $3.600. Year to date, Champions Oncology, Inc.’s stock is down 7.29%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Champions Oncology, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 24, 2025,, no analysts have changed their rating of Champions Oncology, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Champions Oncology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Champions Oncology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Champions Oncology, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Champions Oncology, Inc. (CSBR) by visiting AAII Stock Evaluator.

Relative Price Strength of Champions Oncology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2025, Champions Oncology, Inc. has a weighted four-quarter relative price strength of 15.05%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Champions Oncology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Champions Oncology, Inc. Stock Price: Bottom Line

As of April 25, 2025, Champions Oncology, Inc.’s stock price is $7.945, which is up 4.4% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Champions Oncology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.